Login / Register The Most Trusted Name in Medical Education

Oncology

From breast cancer to myeloma and gastric cancer, Elsevier's Office of Continuing Medical Education offers complimentary CME courses for a variety of oncology subject matters.

1 BANNER

Management of Patients with Relapsed/Refractory Multiple Myeloma: Elsevier CME Independent Conference Highlights from EBMT and EHA 2018

Format: Conference Reporter

*This webcast is not endorsed by the conference organizer. The Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

In this CME-accredited webcast, three experts discuss the clinical implications of some of the latest important research on relapsed/refractory multiple myeloma (RRMM). The roundtable discussion covers new data presented at the 2018 annual meetings of the European Hematology Association (EHA) and the European Society for Blood and Marrow Transplantation (EBMT). The topics discussed include: unmet needs in the treatment of RRMM; new data on treatment strategies (including the roles of proteasome inhibitors, immunomodulatory drugs, and monoclonal antibodies); and emerging treatments, such as chimeric antigen receptor (CAR) T-cell therapies.

Credits: 1.0 AMA PRA Category 1 Credit™
910703 116 x 140

Current and Future Therapies for Cytomegalovirus (CMV) Infection

Format: Webcast

Cytomegalovirus (CMV) infection remains a frequent complication in hematopoietic stem cell transplantation (HSCT) and solid organ transplantation (SOT) recipients. In addition to causing a variety of end-organ diseases, CMV infection is also associated with rejection after SOT and with graft versus host disease (GVHD) after HSCT, as well as with increased risk of secondary bacterial and fungal infections. Antiviral prophylaxis, more commonly used after SOT, is effective against direct and indirect effects of CMV infection, but may lead to overtreatment. Preemptive therapy, more commonly used after HSCT, is based on surveillance, and targets therapy to patients at highest risk. Several antiviral agents are currently available for CMV management; however, their use may be associated with myelosuppression and nephrotoxicity. Novel antiviral therapies with different mechanisms of action are in late-stage development and hold the promise of reducing CMV-related morbidity and mortality.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit(s)™
910750 116 x 140

ESMO 2017: A Therapeutic Update on the Management of Patients with Metastatic Renal Cell Carcinoma

Format: Medical Meeting Reporter

This webcast on metastatic renal cell carcinoma (mRCC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of mRCC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, on September 8–12, 2017. Advances in the use of targeted therapies such as VEGFR inhibitors, novel immunotherapies, and combination therapies including PD-1/PD-L1 and CTLA4 targeting agents will be examined. The experts will address the question of how novel treatment options could be included in individualized treatment plans when approved, to optimize treatment selection and outcomes for patients with mRCC.

Take Course »

 

Credits: 1.0 AMA PRA Category 1 Credit™
910751 116 x 140

ESMO 2017: A Therapeutic Update on the Management of Patients with Gastric Cancer

Format: Medical Meeting Reporter

This webcast on gastric cancer (GC) is based on a roundtable discussion among three key opinion leaders in the field. The experts will present updates on the management of GC and summarize and discuss the latest clinical trial data presented during the ESMO 2017 Congress, held in Madrid, Spain, and the 2017 ASCO Annual Meeting, held in Chicago, USA. Advances in perioperative treatment strategies, targeted therapies such as HER2 inhibitors, and novel immunotherapies including agents targeting PD-1/PD-L1 will be examined. The experts will address the question of how novel treatment options, when approved, could be included in individualized treatment plans, to optimize treatment selection and outcomes for patients with GC.

Take Course »

 

Credits: 1.0 AMA PRA Category 1 Credit™
910752 116 x 140

ESMO 2017: A Therapeutic Update on the Management of Patients with Advanced Hepatocellular Carcinoma

Format: Medical Meeting Reporter

This webcast on hepatocellular carcinoma (HCC) is based on a presentation by an expert, who provides an overview of the advances in the management of HCC and summarizes and discusses the latest data presented during the European Society for Medical Oncology (ESMO) Annual Meeting 2017, held on September 8-12 in Madrid, Spain. Results of clinical trials of targeted therapies that have been evaluated in first-line and second-line setting in advanced HCC and their possible effect on treatment guidelines will be examined. Additionally, the potential role of biomarkers as prognostic factors of response to targeted therapies, particularly in clinical practice, will also be discussed. The expert will also discuss the most promising new agents in advanced clinical trials in HCC and how they might impact the treatment landscape in HCC.

Take Course »

 

Credits: 1.0 AMA PRA Category 1 Credit™
910722e 116 x 140

HOW IMMUNE CHECKPOINT INHIBITORS ARE CHANGING THE TREATMENT LANDSCAPE FOR METASTATIC MELANOMA

Format: Webcast

Metastatic melanoma has a high mortality rate and is refractory to traditional treatments, but recent clinical trials have shown significantly improved patient outcomes with checkpoint inhibitors. However, treating physicians may find its use challenging due to limited clinical experience and confidence in prescribing immunotherapies, especially among patient populations under-represented in clinical trials and in managing immune-related adverse events. This webinar will cover the current practices and challenges in management of metastatic melanoma, as well as insights on the future management of melanoma patients.

Take Course »

 

Credits: 1.00 AMA PRA Category 1 Credit™
ASCO ESMO 116x140

Incorporating Immuno-oncology Agents into Solid and Liquid Tumor Treatment Paradigms: Highlights from ASCO 2017 – Expert Discussion

Format: Webcast

Immunotherapy is now an established treatment approach for patients with cancer across oncology. Immunotherapy agents are a newer type of anticancer drug, and the drugs in the largest class, checkpoint inhibitors, block the checkpoint pathways that cancer cells use to shut down the patient’s immune system. Checkpoint inhibitors are associated with more durable clinical responses compared to both small molecule targeted therapy and conventional chemotherapy (CT). Because checkpoint inhibitors have unique mechanisms of action, they also produce immune-related adverse events and response patterns that are markedly distinct from targeted agents or conventional CT. The 5 currently available immunotherapy agents have 18 indications across multiple cancer types. Checkpoint inhibitors demonstrate the potential to change current cancer treatment paradigms.                        

In this interactive CE activity, a leading medical oncologist discusses highlights of several key presentations from the 2017 American Society of Clinical Oncology (ASCO) Annual  Meeting on the use of checkpoint inhibitors in several cancer types. Topics include questions on appropriate clinical setting for immunotherapy (eg, refractory cancer), dose, combination therapy, treatment beyond progression, and side-effect profile for patients.

Take Course »

Credits: 0.5 AMA PRA Category 1 Credit™
ASCO ESMO 116x141

ASCO & ESMO 2017 Highlights: Incorporating Immuno-oncology Agents into Solid and Liquid Tumor Treatment Paradigms

Format: Webcast

 The goal of this initiative is to help medical oncology and hematology-oncology physicians and advanced practitioners in community and academic settings to integrate checkpoint inhibitors into cancer treatment regimens and understand their unique safety and response profiles.

Take Courses »

 

Credits: Earn up to 2.0 AMA PRA Category 1 Credit(s)™
MEDX ONC 116x140

Patient-Centered Care for Genitourinary Cancers

Format: Webcast

Community oncologists are challenged to stay up to date with updated clinical practice guidelines on the personalization of treatments for genitourinary (GU) cancers, including prostate, urothelial, and renal cancers, combination/sequential therapies, emerging safety and efficacy data from ongoing studies of novel regimens, and strategies to facilitate patient engagement in order to improve patient outcomes. Clinicians need tools and resources to help educate their patients and empower them to participate in their care and make educated treatment choices. Advanced-stage GU cancers consists of a spectrum of disease that requires an integrated multidisciplinary approach supported by a uro-oncologic team. Therefore, it is critical to educate these clinicians on their roles within the multidisciplinary cancer care team and on the importance of effective communication with other members of the team to maximize patient outcomes.

Take Course »

Credits: 1.25 AMA PRA Category 1 Credits™ ; 1.2 Nursing contact hours; 1.25 ACPE hours
910733 116 x 140

Integrating Biosimilars into Supportive Care: Insights for Informed Decisions

Format: Webcast

Biosimilars, which have been available in Europe for more than 10 years, are increasingly gaining regulatory approval in the United States. These agents have the potential to contain rapidly increasing health care costs and simultaneously enable greater patient access. The cornerstone of broad acceptance of biosimilars is increased education of all involved parties regarding regulatory standards for biosimilar approval, preclinical and clinical data requirements, interchangeability, and extrapolation of indications.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
Elsevier Website Pleural Web 116x140 p2 thumbnail

Learning Center Progress in Pleural Mesothelioma

Format: Resource Center

Welcome to Progress in Pleural Mesothelioma, an Elsevier Learning Center. The aim of this learning center is to increase clinical knowledge by providing continuing medical education (CME) activities, research articles, and resources for health care professionals (HCPs) who treat patients with pleural mesothelioma.

Take Course »

Credits: 0.5 AMA PRA Category 1 Credit™
Elsevier SITC ASCO 2018 01 Web 116x140 webcast

The IO Quiz Show: Biomarkers for Immunotherapy

Format: Webcast

This webcast was recorded at a live event at ASCO SITC 2018. During this event, three leading experts challenged participants with quiz questions, which formed a basis for in-depth discussions supported by slide presentations. Participants were able to test and expand their knowledge on the increasingly important role of biomarkers in immuno-oncology. The experts examined the tumor microenvironment and addressed the evidence base for, and the future potential of, current and emerging biomarkers in guiding treatment decisions and in predicting the response to immuno-oncology therapeutics. Participants also learned about the role and importance of next-generation sequencing for the evaluation of novel immune biomarkers and for daily clinical practice.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credits™
Thumbnail 116x140 LearningCenter v2

Progress in Pancreatic Cancer

Format: Resource Center

Welcome to the Progress in Pancreatic Cancer Learning Center. This Learning Center is a freely accessible, educational platform for healthcare providers who treat patients with pancreatic cancer

Our goal is to ensure that you – the practicing clinician – have access to the most accurate, up-to-date information for the treatment of patients with pancreatic cancer. Within this learning center, you will have access to complimentary continuing medical education (CME) activities highlighting up-to-the-minute emerging evidence that can be applied to everyday practice. Additional resources include open access to the full text of relevant peer-reviewed articles, clinical guidelines, interactive infographics, and other materials dedicated to helping you improve patient care.

As new data emerge, we will be updating the Progress in Pancreatic Cancer Learning Center with new CME activities and timely materials, so please check back often for the latest offerings.

We know you will find these resources helpful in your clinical practice, and hope that you will make the Progress in Pancreatic Cancer Learning Center your destination for pancreatic cancer education.

Take Course »

Credits: 0.75 AMA PRA Category 1 Credit™ per module
Bladder Cancer banner 116x140

Management of Patients with Bladder Cancer, Elsevier CME Independent Conference Highlights of the ASCO-GU Genitourinary Cancer Symposiums 2018*

Format: Webcast

This conference reporter webcast on bladder cancer is based on a roundtable discussion by three experts. During the webcast they provide an overview of challenges in the management of bladder cancer and summarize and discuss recent data presented during the ASCO-GU 2018 Symposium. The experts examine clinical trial outcomes of immunotherapies for bladder cancer and address the question of how current, novel, and emerging treatment options (when approved) could be implemented in individualized treatment plans to optimize treatment selection and outcomes for patients with bladder cancer.

*This webcast is not endorsed by the conference organizer. The Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit™
Colorectal Cancer banner 116x140

Management of Patients with Colorectal Cancer, Elsevier CME Independent Conference Highlights of the ASCO-GI 2018 Annual Meeting*

Format: Webcast

*This webcast is not endorsed by the conference organizer. The Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

This conference reporter webcast on colorectal cancer is based on a roundtable discussion by three experts. During the webcast they provide an overview of challenges in the management of colorectal cancer and summarize and discuss recent data presented during the ASCO-GI 2018 Symposium. The experts examine clinical trial outcomes of targeted therapies for colorectal cancer and address the question of how current, novel, and emerging treatment options (when approved) could be implemented in individualized treatment plans to optimize treatment selection and outcomes for patients with colorectal cancer.

Credits: 1.0 AMA PRA Category 1 Credit™
ASH 2017 IMMUNO banner 116x140 thumbnail

Immunotherapy in Hematological Malignancies

Format: Webcast

This is a CME-accredited Elsevier Conference Reporter webcast based on a virtual roundtable discussion on immunotherapy in hematological malignancies. During the discussion three key opinion leaders summarize and give their expert opinion on important data from abstracts presented at the American Society of Hematology (ASH) 2017 Annual Meeting. The webcast lasts approximately 1 hour.

*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference coverage educational programs.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
ASH 2017 Update MM banner 116x140

Management of Patients With Relapsed and/or Refractory Multiple Myeloma

Format: Webcast

This is a CME-accredited Elsevier Conference Reporter webcast based on a virtual roundtable discussion on the management of patients with relapsed and/or refractory multiple myeloma. During the virtual roundtable discussion, 3 experts summarize and give their expert opinion on important data from abstracts presented at the American Society of Hematology Association (ASH) 2017 Annual Meeting.

*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis, and expert perspectives through conference-coverage educational programs.

Take Course »

Credits: 1.00 AMA PRA Category 1 Credit(s)™
2017 23 Modules 3 116x140

Evolving Paradigms for Managing Prostate Cancer: Implementing Multimodal Therapy in the Community Setting

Format: Webcast

Over the past 13 years, several new agents have been approved to treat patients with metastatic prostate cancer (PC). As a result, clinical guidelines have been updated frequently that support the expanding the role of combination therapy, particularly by introducing chemotherapy earlier to patients with castrate-sensitive progressive disease. Community urologists often treat PC patients many years before the development of progressive disease, and a growing number of urologists have successfully implemented advanced prostate cancer clinics (APCCs) within their practice setting in order to do so. This interactive activity will discuss the benefits of creating an APCC as well as all of the infrastructure requirements and practical considerations for administering chemotherapy in an office setting, as well as the financial ramifications of this investment in time and resources.

Take Course »

Credits: 1.0 AMA PRA Category 1 Credit™
910791 116 x 140

The Role of Oncolytic Viral Therapy in the Management of Patients with Metastatic Melanoma

Format: Webcast

This CME program will delve into the role of oncolytic viral therapy in the treatment and management of the metastatic melanoma patients, highlighting data presented at the Maui and Hawaii Dermatology 2018 annual meetings. The three expert faculty will review the immunotherapy for melanoma, followed by a discussion of recent safety and efficacy trial data for this emerging therapeutic option. Practical strategies for safely utilizing oncolytic viral therapies in clinical practice as well as best practices for engaging the interprofessional team will be relayed to the learner through an discussion-based format.

*This webcast is not endorsed by the conference organizer. Elsevier Office of Continuing Medical Education is an independent medical education company that provides clinical updates, analysis and expert perspectives through conference coverage educational programs.

Take Course »

 

Credits: 1.0 AMA PRA Category 1 Credit™